MX2022011112A - Metodos para tratar la diarrea o afecciones inflamatorias del intestino. - Google Patents

Metodos para tratar la diarrea o afecciones inflamatorias del intestino.

Info

Publication number
MX2022011112A
MX2022011112A MX2022011112A MX2022011112A MX2022011112A MX 2022011112 A MX2022011112 A MX 2022011112A MX 2022011112 A MX2022011112 A MX 2022011112A MX 2022011112 A MX2022011112 A MX 2022011112A MX 2022011112 A MX2022011112 A MX 2022011112A
Authority
MX
Mexico
Prior art keywords
gut
methods
inflammatory conditions
treating diarrhea
subject
Prior art date
Application number
MX2022011112A
Other languages
English (en)
Inventor
Suzette Pereira
Ricardo Rueda
Vadivel Ganapathy
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2022011112A publication Critical patent/MX2022011112A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Pediatric Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para tratar la diarrea o una afección inflamatoria del intestino en un sujeto comprende administrarle una cantidad con eficacia terapéutica de beta-hidroxi-beta-metilbutirato (HMB) o una sal de este a un sujeto que lo necesite. Un método para tratar la diarrea con secreción en un sujeto comprende administrarle una cantidad con eficacia terapéutica de HMB o una sal de este a un sujeto que presente uno o más de los siguientes síntomas: pérdida de líquidos del intestino, pérdida de electrolitos del intestino, deshidratación o inflamación del intestino.
MX2022011112A 2020-03-12 2021-03-11 Metodos para tratar la diarrea o afecciones inflamatorias del intestino. MX2022011112A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062988565P 2020-03-12 2020-03-12
PCT/US2021/021864 WO2021183740A1 (en) 2020-03-12 2021-03-11 Methods of treating diarrhea or inflammatory conditions of the gut

Publications (1)

Publication Number Publication Date
MX2022011112A true MX2022011112A (es) 2022-10-07

Family

ID=75426679

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011112A MX2022011112A (es) 2020-03-12 2021-03-11 Metodos para tratar la diarrea o afecciones inflamatorias del intestino.

Country Status (7)

Country Link
US (1) US20230112641A1 (es)
EP (1) EP4117646A1 (es)
JP (1) JP2023519170A (es)
CN (1) CN115209886A (es)
CA (1) CA3171034A1 (es)
MX (1) MX2022011112A (es)
WO (1) WO2021183740A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
TWI526161B (zh) * 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
JP6920199B2 (ja) * 2014-08-25 2021-08-18 アナタラ・ライフサイエンスズ・リミテッド 抗微生物剤耐性を回避する抗下痢製剤
US20160184248A1 (en) * 2014-12-15 2016-06-30 University Of Central Florida Research Foundation Inc. Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response
CN109770078B (zh) * 2019-02-21 2022-04-29 山东省农业科学院畜牧兽医研究所 一种预防哺乳期犊牛腹泻的饲料添加剂及其使用方法

Also Published As

Publication number Publication date
CA3171034A1 (en) 2021-09-16
WO2021183740A1 (en) 2021-09-16
CN115209886A (zh) 2022-10-18
JP2023519170A (ja) 2023-05-10
US20230112641A1 (en) 2023-04-13
EP4117646A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
Han et al. Dietary intake of whole strawberry inhibited colonic inflammation in dextran-sulfate-sodium-treated mice via restoring immune homeostasis and alleviating gut microbiota dysbiosis
Lai et al. Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide
Malfertheiner The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer
Nishizawa et al. Effect of supplementation with rebamipide for H elicobacter pylori eradication therapy: A systematic review and meta‐analysis
MX2021014302A (es) Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
De Vries et al. Helicobacter pylori infection and nonmalignant diseases
MX2022000559A (es) Metodos para la administracion de ciertos inhibidores de vmat2 a pacientes con insuficiencia renal grave.
RU2016136638A (ru) Применение режима краткосрочного голодания в сочетании с ингибиторами киназ для усовершенствования традиционной химио-лекарственной эффективности и пригодности и обращения вспять побочных эффектов от киназ в нормальных клетках и тканях
EA201890784A1 (ru) Резьбовое соединение для стальной трубы
MX2022011112A (es) Metodos para tratar la diarrea o afecciones inflamatorias del intestino.
WO2009033009A3 (en) Antibodies against flagellin and uses thereof
Anzoise et al. Potential usefulness of methyl gallate in the treatment of experimental colitis
Di Iorio et al. Urea and impairment of the Gut-Kidney axis in Chronic Kidney Disease
SG11202110027XA (en) Polyalkyl(meth)acrylates for improving fuel economy, dispersancy and deposits performance
MX2017015926A (es) Uso de derivados de bencimidazol para escape acido nocturno.
Iijima et al. Risk factors for upper GI damage in low-dose aspirin users and the interaction between H. pylori infection and low-dose aspirin use
BR112018072741A2 (pt) método para a profilaxia de infecção pelo vírus da zika
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
EA201891752A2 (ru) Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования
EA201991716A1 (ru) АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ГЕНТИНГТОНА
MX2022015959A (es) Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
Ardalan et al. An update on Helicobacter pylori infection in renal failure patients
Papineni et al. Membranous glomerulonephritis secondary to Borrelia burgdorferi infection presenting as nephrotic syndrome
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
EA202091679A1 (ru) Стабильные композиции кортикостероидов